Enhertu — The FDA on May 5 broadened its approval for AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, which goes by the brand name Enhertu, to include adult patients with unresectable or metastatic HER2-positive breast cancer who have previously been treated with an anti-HER2-based regimen.
Camzyos — The FDA on April 28 approved Bristol Myers Squibb’s Camzyos, which goes by the chemical name mavacamten, for adults with symptomatic obstructive hypertrophic cardiomyopathy.
Vivjoa — Oteseconazole, which goes by the brand name of Vivjoa, was approved on April 26 to reduce the incidence of recurrent vulvovaginal candidiasis in women with a history of the condition who are not of reproductive potential.
Pluvicto — Lutetium (Lu 177) vipivotide tetraxetan, which goes by the brand name Pluvicto, was approved on March 23 to treat adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after other therapies.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
